Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results

Rhea-AI Summary

Oncolytics Biotech (NASDAQ: ONCY), a clinical-stage immunotherapy company focused on pelareorep development, has scheduled its 2025 Annual General Meeting for August 8, 2025, at 10:00 a.m. ET. The meeting will be held virtually, with CEO Jared Kelly providing a corporate update and discussing strategic milestones for 2025 after the formal shareholder voting.

The company will also release its second quarter 2025 financial results before market opening on the same day. Shareholders can access detailed voting information through the Management Information Circular dated June 18, 2025, available on the company's website and in securities filings.

News Market Reaction

+7.58%

12 alerts

+7.58% News Effect

+8.6% Peak in 5 hr 52 min

+$7M Valuation Impact

$98M Market Cap

0.9x Rel. Volume

On the day this news was published, ONCY gained 7.58%, reflecting a notable positive market reaction. Argus tracked a peak move of +8.6% during that session. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $7M to the company's valuation, bringing the market cap to $98M at that time.

Data tracked by StockTitan Argus on the day of publication.

The management team will provide a brief corporate update after the formal portion of the shareholder meeting

SAN DIEGO and CALGARY, AB, Aug. 5, 2025 /PRNewswire/ -- Oncolytics Biotech^® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today announced that its upcoming 2025 Annual General Meeting (the "Meeting") will be held virtually at 10:00 a.m. Eastern Time (ET) on Friday, August 8, 2025, as a virtual-only shareholder meeting. After the Meeting and at the conclusion of shareholder voting, Oncolytics' Chief Executive Officer, Jared Kelly, will provide a corporate update, including strategic milestones for the remainder of 2025. Financial results for the second quarter of 2025 will also be announced before the stock market opens on the same day.

 

 

To access the Meeting as a guest only (non-voting attendee):

• Visit the webcast site: https://virtual-meetings.tsxtrust.com/en/1824/
• Click the button "I am a Guest" and complete the form
• If necessary, provide the case-sensitive password: onc2025

Information on how to vote your shares by proxy and attend the Meeting as a shareholder is available in the Company's most recent Management Information Circular (the "Circular") dated June 18, 2025. The Circular is available on the Reports page of the investor relations section of the Company's website at https://oncolyticsbiotech.com/investor-overview/filings/reports/ and in Canadian and American securities filings.

Registered shareholders (who have not appointed a proxyholder) and duly appointed proxyholders (including non-registered shareholders who appoint themselves as proxyholders) will be able to virtually attend the Meeting and vote in real-time, provided they are connected to the internet. Non-registered shareholders who have not properly appointed themselves as proxyholder will be able to attend the Meeting as guests but will not be able to vote at the Meeting.

About Oncolytics Biotech Inc.

Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and early-phase studies in pancreatic and colorectal cancer. It induces anti-cancer immune responses by converting immunologically "cold" tumors "hot" through the activation of innate and adaptive immune responses.

The Company is advancing pelareorep in combination with chemotherapy and checkpoint inhibitors in metastatic breast and pancreatic cancers, both of which have received Fast Track designation from the FDA. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.

Logo: https://mma.prnewswire.com/media/2408622/Oncolytics_Biotech_Inc_Logo.jpg

Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca

Investor Relations for Oncolytics
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com

Media Contact for Oncolytics
Owen Blaschak
LifeSci Communications
oblaschak@lifescicomms.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/oncolytics-biotech-announces-upcoming-annual-general-meeting-and-second-quarter-financial-results-302521769.html

SOURCE Oncolytics Biotech® Inc.

FAQ

When is Oncolytics Biotech (ONCY) 2025 Annual General Meeting?

The Annual General Meeting will be held virtually on Friday, August 8, 2025, at 10:00 a.m. Eastern Time (ET).

How can shareholders attend the ONCY virtual Annual General Meeting 2025?

Shareholders can attend by visiting https://virtual-meetings.tsxtrust.com/en/1824 and using the password 'onc2025'. Registered shareholders and appointed proxyholders can vote in real-time.

When will Oncolytics Biotech (ONCY) release Q2 2025 earnings?

Oncolytics Biotech will release its second quarter 2025 financial results before the stock market opens on August 8, 2025.

Who will present at the Oncolytics Biotech 2025 Annual Meeting?

CEO Jared Kelly will provide a corporate update and discuss strategic milestones for the remainder of 2025 after the conclusion of shareholder voting.